Clinical trials: Locally Advanced Colorectal Cancer
Rectal Cancer
Trial Evaluating 3-year Disease Free Survival in Patients With Locally Advanced Rectal Cancer Treated With Chemoradiation Plus Induction or Consolidation Chemotherapy and Total Mesorectal Excision or Non-operative Management
The study is designed to test the hypothesis that patients with Locally advanced rectal cancer ( LARC) treated with Total neoadjuvant therapy (TNT) and Total mesorectal excision (TME) or Non-operative management (NOM) will have…
- Trial name
- NCT02008656
- Testing
- Oxaliplatin (OXAL), 5-Fluorouracil (5-FU), Leucovorin
- Where
- 26 sites in United States
- Volunteers
- 358 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Patients With Locally Advanced Rectal Cancer
GEMCAD-REVEAL STUDY - Circulating Tumor DNA as a Predictor of Relapse in Patients With Locally Advanced Rectal Cancer.
The evaluation of the tumor response to chemoradiotherapy/total neoadjuvant therapy (CRT/TNT) remains a challenge. The integration of a blood-based biomarker such as ctDNA with clinico-radiological tools could offer the potential…
- Trial name
- REVEAL (NCT05674422)
- Testing
- total neoadjuvant therapy
- Where
- 15 sites in Spain
- Volunteers
- 120 people
- Sponsor
- Grupo Espanol Multidisciplinario del Cancer Digestivo
Solid Tumor, Adult, Solid Tumor
A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression
The goal of this study is to test A2B530,an autologous logic-gated Tmod™ CAR T-cell product in subjects with solid tumors including colorectal cancer (CRC), pancreatic cancer (PANC), non-small cell lung cancer (NSCLC), and other…
- Conditions
- Solid Tumor, Adult, Solid Tumor, Pancreatic Cancer, Pancreatic Neoplasms
- Trial name
- EVEREST-1 (NCT05736731)
- Testing
- A2B530, xT-Onco with HLA-LOH Assay
- Where
- 8 sites in United States
- Volunteers
- 160 people
- Sponsor
- A2 Biotherapeutics Inc.
Colorectal Cancer (Diagnosis)
Neoadjuvant Therapy for Locally Advanced Low Rectal Cancer (SMARTi-RC01)
The goal of this clinical trial is to learn if combining serplulimab (PD-1 inhibitor) with bevacizumab and short-course total neoadjuvant therapy (TNT) works to treat locally advanced mid-to-low rectal cancer in adults.
- Trial name
- SMARTi-RC01 (NCT07134101)
- Testing
- Serplulimab, Bevacizumab, Short-Course Radioterapy
- Volunteers
- 138 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Colorectal Cancer
Neo-adjuvant Chemoradiation With Oxaliplatin/5-FU in Rectal Cancer
RATIONALE: 5FU based neoadjuvant chemoradiation (nCRT) is the standard of care for Stage II/III rectal cancer. Pathologic complete response (pCR) and downstaging have been associated with improved outcomes.
- Trial name
- NCT00831181
- Testing
- 5-FU, Oxaliplatin, leucovorin
- Where
- 2 sites in United States
- Volunteers
- 27 people
- Sponsor
- Beth Israel Medical Center
Colon Cancer, Rectal Cancer
Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer
The purpose of the Phase Ib portion is to find out the highest dose of study drug that can safely be given when tested in a small group of subjects.
- Trial name
- NCT01347645
- Testing
- FOLFIRI, E7820
- Where
- 38 sites in United States, Argentina and 4 more
- Volunteers
- 82 people
- Sponsor
- Eisai Inc.
Rectal Cancer
Cetuximab (Erbitux®), Capecitabine and Radiotherapy in Neoadjuvant Treatment of Patients With Rectal Cancer
This is a nonrandomised pilot trial to establish the role of intravenous cetuximab when added to a schedule of capecitabine plus pelvic radiation in patients who have locally advanced primary resectable rectal cancers.
- Trial name
- XERT (NCT00689702)
- Testing
- cetuximab, capecitabine
- Where
- Slovenia
- Volunteers
- 43 people
- Sponsor
- Institute of Oncology Ljubljana
Locally Advanced Rectal Cancer
TIME in Immunotherapy Combined With nCRT for Rectal Cancer
This is an open-label, prospective phase II clinical trial to evaluate the therapeutic and prognostic implications of tumor immune microenvironment in the neoadjuvant immunotherapy combined with chemoradiotherapy for patients…
- Trial name
- TIMENT-R (NCT05507112)
- Testing
- PD-1 inhibitor, Capecitabine, Long-course radiation therapy
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Peking Union Medical College Hospital
MSI-H/dMMR Gastric Carcinoma and Colorectal Cancer
AK104 in Locally Advanced MSI-H/dMMR Gastric Carcinoma and Colorectal Cancer
This is a single-arm, multicenter phase II clinical study. The aim is to evaluate the safety, tolerability, and anti-tumor activities of AK104(a PD-1/CTLA-4 bispecific antibody) in MSI-H/dMMR locally advanced gastric…
- Trial name
- NCT04556253
- Testing
- AK104
- Where
- China
- Volunteers
- 47 people
- Sponsor
- Peking University
Colon Cancer
Neoadjuvant CAPOX Plus Ivonescimab Versus CAPOX for Locally Advanced Colon Cancer
Neoadjuvant chemotherapy has been validated by several clinical studies to achieve preoperative downstaging and improve survival outcomes in patients with locally advanced colon cancer .
- Trial name
- NCT06790212
- Testing
- Ivonescimab, Oxaliplatin, Capecitabine
- Volunteers
- 168 people
- Sponsor
- Sun Yat-sen University
Rectal Carcinoma
Neoadjuvant Treatment for Advanced Rectal Carcinoma
The purpose of the study is to compare pre-operative radio-chemotherapy (RT + capecitabine) to a short course RT associated with a delayed surgery, with two primary objectives: the efficacy evaluation (rate of R0 resection) and…
- Trial name
- NACRE (NCT02551237)
- Testing
- 50 Gy, Capecitabine, 25 Gy
- Where
- 37 sites in France
- Volunteers
- 103 people
- Sponsor
- UNICANCER
Colorectal Cancer
FR901228 in Treating Patients With Previously Treated Unresectable Locally Advanced or Metastatic Colorectal Cancer
RATIONALE: Drugs used in chemotherapy, such as FR901228, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00077337
- Testing
- romidepsin
- Where
- 88 sites in United States
- Sponsor
- SWOG Cancer Research Network
Locally Advanced Rectal Cancer
Neoadjuvant Bevacizumab, Capecitabine and Radiation Therapy With or Without Oxaliplatin Locally Advanced Rectal Cancer
Phase II clinical trial, open-label, randomized, two arms, multicentre (possibly multinational). Academic, investigator initiated.
- Trial name
- AXEBEAM (NCT00828672)
- Testing
- Oxaliplatin, Bevacizumab, Capecitabine
- Where
- 9 sites in Belgium
- Volunteers
- 84 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Colorectal Cancer
Study Using Fluorine-18-Labeled Fluoro-Misonidazole Positron Emission Tomography to Detect Hypoxia in Locally Advanced (T3-T4 and./or N1)Primary Rectal Cancer Patients
When used with a different radioactive tracer called FMISO, a PET scan can find areas of low oxygen in the tumor. We think that having areas of low oxygen is a reason why some tumors are hard to treat with radiation.
- Trial name
- NCT00574353
- Testing
- Fluorine-18-Labeled Fluoro-Misonidazole Positron Emission
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Advanced Cancer, Advanced Solid Tumor
NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
This study is an open-label, multi-arm, parallel cohort, dose validation and expansion design. The study is modular in design, allowing evaluation of the safety, efficacy and pharmacokinetics (PK) of NUC-3373 in combination with…
- Conditions
- Advanced Cancer, Advanced Solid Tumor, Neoplasm Malignant, Metastatic Cancer
- Trial name
- NCT05714553
- Testing
- Fosifloxuridine Nafalbenamide, Leucovorin, Pembrolizumab
- Where
- 4 sites in United Kingdom
- Volunteers
- 19 people
- Sponsor
- NuCana plc
Rectal Cancer
Capecitabine,Oxaliplatin & Erbitux Given Throughout Multi-Modal Therapy for Locally Advanced Rectal Adenocarcinoma
This is a phase II study of induction chemotherapy (capecitabine, oxaliplatin and cetuximab (erbitux)) followed by capecitabine, oxaliplatin, cetuximab and radiotherapy followed by surgery followed by adjuvant capecitabine…
- Trial name
- NCT00353457
- Testing
- Capecitabine, Oxaliplatin and Cetuximab, Radiation
- Volunteers
- 6 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Rectal Cancers.
Preoperative Concurrent Chemotherapy and Intensity Modulated Radiotherapy (IMRT) in Locally Advanced Rectal Cancer
The hypothesis of this study is that dose escalated intensity modulated radiotherapy (IMRT) to a dose of 55Gy in 25# to primary rectal tumor concurrent with oral capecitabine results in an improved pathological response rate from…
- Trial name
- NCT01340508
- Testing
- Intensity Modulated Radiotherapy
- Where
- Singapore
- Volunteers
- 63 people
- Sponsor
- National University Hospital, Singapore
Metastatic Colorectal Cancer
A Study of ES104 in Patients With Metastatic Colorectal Cancer
The purpose of this open-label, Multicenter Phase I/II study is to evaluate the safety, tolerability, preliminary anti-tumor efficay, pharmacokinetics, anti-drug antibodies and biomarkers of ES104 in patients with unresectable…
- Trial name
- NCT05167448
- Testing
- ES104
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Elpiscience (Suzhou) Biopharma, Ltd.
Metastatic Colorectal Cancer
Assessment of Clinical Practice Administration of Chemotherapy and Anti-angiogenic Agent (Bevacizumab) in Colorectal Cancer
Investigators propose to assess, retrospectively (from 1/7/2009) and prospectively (up to 31/12/2013,) the safety and tolerability profile (number of participants with adverse events) of standard chemotherapy and anti-angiogenic…
- Trial name
- NCT01811108
- Where
- 6 sites in Greece
- Volunteers
- 670 people
- Sponsor
- Hellenic Oncology Research Group
Colorectal Cancer
A Clinical Trial Evaluating TQB2930 Injection and Chemotherapy With or Without Bevacizumab in Patients With HER2-Abnormally Expressed Unresectable Locally Advanced or Metastatic Colorectal Cancer.
To assess the safety and preliminary efficacy of TQB2930 and chemotherapy with or without bevacizumab in sparticipants with HER2-Abnormally Expressed locally advanced or metastatic colorectal cancer (CRC).
- Trial name
- NCT07653685
- Testing
- TQB2930 injection +(Oxaliplatin for injection + Capecitabine tablets)/( Irinotecan hydrochloride injection+ Capecitabine tablets)+Bevacizumab injection, TQB2930 injection +(Oxaliplatin for injection + Capecitabine tablets)/( Irinotecan hydrochloride injection+ Capecitabine tablets)
- Where
- 31 sites in China
- Volunteers
- 71 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.